Research Paper Volume 12, Issue 2 pp 1867—1887

Figure 9. miR-106b-5p promoted the cell proliferation in T47D and CAMA-1 cells by targeting CNN1 and activating the Rho/ROCK1 signaling pathway. (A) The ZINC00881524 was successfully inhibited the protein expression of ROCK1 after the cells were treated with ZINC00881524 for 24 h. ZINC00881524 is the inhibitor of the Rho/ROCK1 pathway. The protein expression of ROCK1 was detected by immunoblotting assay. (B) The CCK8 assay demonstrated that Rho/ROCK1 inhibitor alleviated the cell proliferation compared with the treatment of CNN1 siRNA. si-CNN1, the cells were transfected with CNN1 siRNA. ZINC00881524+si-CNN1, the cells were co-transfected with ZINC00881524 and CNN1 siRNA. *P<0.05 vs. Control and **P<0.001 vs. Control. #P<0.05 vs. si-CNN1. #P<0.001 vs. si-CNN1. (C) The protein expression of ROCK1 was upregulated by transfection of miR-106b-5p mimic, but co-transfection of miR-106b-5p and ZINC00881524 could downregulate it. mimic, the cells were transfected with miR-106b-5p mimic. mimic+ ZINC00881524, the cells were co-transfected with miR-106b-5p mimic and ZINC00881524. *P<0.05 vs. Control and **P<0.001 vs. Control. (D) Co-transfection of miR-106b-5p and ZINC00881524 alleviated the positive effect of miR-106b-5p mimic on cell proliferation in T47D and CAMA-1 cells. mimic, the cells were transfected with miR-106b-5p mimic. mimic+ ZINC00881524, the cells were co-transfected with miR-106b-5p mimic and ZINC00881524. *P<0.05 vs. Control and **P<0.001 vs. Control. #P<0.05 vs. mimic. #P<0.001 vs. mimic. (E) The signaling cascade indicated that miR-106b-5p promoted breast cancer by targeting CNN1 and activating the Rho/ROCK1 signaling pathway.